“Upon authorization of our investigational COVID-19 vaccine for emergency use, we are ready to begin shipping,” Paul Stoffels, the company’s chief scientific officer, said in a statement. “We are working with great urgency to make our investigational vaccine available to the public as quickly as possible.”